CN1771977A - Notoginseng glycol-saponin composition and its prepn and use - Google Patents
Notoginseng glycol-saponin composition and its prepn and use Download PDFInfo
- Publication number
- CN1771977A CN1771977A CNA2004100906050A CN200410090605A CN1771977A CN 1771977 A CN1771977 A CN 1771977A CN A2004100906050 A CNA2004100906050 A CN A2004100906050A CN 200410090605 A CN200410090605 A CN 200410090605A CN 1771977 A CN1771977 A CN 1771977A
- Authority
- CN
- China
- Prior art keywords
- notoginseng
- ethanol
- glycol
- saponin composition
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 98
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 98
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 21
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 12
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims abstract description 7
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 claims abstract description 7
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000000552 rheumatic effect Effects 0.000 claims abstract description 7
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 128
- 239000000843 powder Substances 0.000 claims description 30
- 239000011347 resin Substances 0.000 claims description 18
- 229920005989 resin Polymers 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 14
- 239000000741 silica gel Substances 0.000 claims description 14
- 229910002027 silica gel Inorganic materials 0.000 claims description 14
- 229960001866 silicon dioxide Drugs 0.000 claims description 14
- 229930182494 ginsenoside Natural products 0.000 claims description 13
- 229940089161 ginsenoside Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 238000005325 percolation Methods 0.000 claims description 9
- 208000025747 Rheumatic disease Diseases 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000007654 immersion Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 17
- 230000000202 analgesic effect Effects 0.000 abstract description 4
- 201000003068 rheumatic fever Diseases 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 abstract 3
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 abstract 3
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 abstract 3
- 230000001741 anti-phlogistic effect Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 239000012264 purified product Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000013641 positive control Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 7
- 229960000905 indomethacin Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012567 medical material Substances 0.000 description 6
- 206010042674 Swelling Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 4
- 230000001760 anti-analgesic effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000002917 insecticide Substances 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 235000002791 Panax Nutrition 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- -1 diol saponins Chemical class 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 2
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical group 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 240000000920 Typhonium flagelliforme Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
The present invention belongs to the field of Chinese medicine, and is especially the purified product of notoginseng as one kind of Chinese medicinal materials and its preparation process and pharmaceutical use. The notoginseng glycol-saponin composition obtained through purifying notoginseng consists of ginsenoside Rb1 and ginsenoside Rd as main components, and contains ginsenoside Rb1 30-70 wt% and ginsenoside Rd 4-18 wt%, with the total content of ginsenoside Rb1 and ginsenoside Rd being up to 80 wt%. The notoginseng glycol-saponin composition has obvious antiflogistic and analgetic effect, low toxicity, and the features of nonsteroidal antiphlogistic. The composition may be used in preparing medicine for treating rheumatic and rheumatoid arthritis.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to purification thing and preparation method thereof and the pharmaceutical applications of Chinese medicine Radix Notoginseng.
Background technology
Radix Notoginseng (Panax notoginseng (Burk.) F.H.chen) claim Radix Notoginseng, Panax pseudoginseng, Typhonium flagelliforme (Lodd.) Blume, mountain lacquer, Radix Stephaniae Sinicae (Radix Stephaniae Dielsianae) and Herba Wedeliae Wallichii etc. again, be Araliaceae (Araliaceae) Panax (Panax Linn) herbaceos perennial, adopt and long three petioles of every strain because of digging in its after planting three to seven years, each petiole is given birth to seven blades, so name Radix Notoginseng, its stem, leaf, Hua Junke are used as medicine, and are Chinese distinctive rare Chinese medicines.According to relevant document record, Radix Notoginseng was used historical nearly 600 years, nearly 500 years of cultivation history.Radix Notoginseng is because of it has significant blood circulation promoting and blood stasis dispelling with regard to being acknowledged as since ancient times, the subduing swelling and relieving pain effect is described as " Radix Stephaniae Sinicae (Radix Stephaniae Dielsianae) ", " southern part of the country SHENCAO ".
(publication number: CN1083819A discloses day to Chinese patent application 93105774: the preparation method that on March 16th, 1994) discloses a kind of Radix Notoginseng total arasaponins.(publication number: CN1334267A discloses day to Chinese patent application 01108591: the preparation method that on February 6th, 2002) also discloses a kind of Radix Notoginseng total arasaponins.Chinese patent application 02144840 (publication number: CN1412162A, on April 23rd, 2003), 02158727 (publication number: CN1424321A, open day: on June 18th, 2003) also all disclose a kind of method of from stem and leaf of Radix Notoginseng, extracting Radix Notoginseng total arasaponins respectively open day:.
The described method of above-mentioned Chinese patent application all is to extract or the preparation Radix Notoginseng total arasaponins.Radix Notoginseng total arasaponins belongs to the dammarane type four-ring triterpenoid saponins, can be further divided into protopanoxadiol type and Protopanaxatriol's type two classes according to its construction features.Because the difference of this two saponins structure, their biologic activity also differs widely, and panoxadiol's type saponin has stronger direct anti-inflammatory and analgesic effect, and protopanaxatriol ginsenoside then has stronger anticoagulant, suppresses thrombotic effect.And given play to bigger drug effect targetedly based on the pharmaceutical preparation of this Radix Notoginseng total arasaponins is very difficult at concrete disease at present.Therefore, people need isolate the effective site that contains different component from Radix Notoginseng, so that can provide the Radix Notoginseng medicine that concrete disease is fit to more.
Rheumatoid arthritis is a kind of systemic autoimmune disease based on arthropathy, and pathological changes often spreads all over whole body, invades blood, lung, nerve and cardiovascular, is a kind of " pertinacious disease " of serious harm human health.Up to the present, the ideal medicament of still not having treatment rheumatic, rheumatoid arthritis.Though Radix Notoginseng is used for the treatment of the historical of long standing and well established of traumatic injury, subduing swelling and relieving pain, at present also not about from Radix Notoginseng, extracting the report that effectively to treat the medicine of rheumatic, rheumatoid arthritis.Therefore, people need isolate the significant composition of anti-inflammatory and analgesic effect from Radix Notoginseng, so that can provide the Radix Notoginseng medicine that rheumatic, rheumatoid arthritis disease are fit to more.
Summary of the invention
An object of the present invention is to provide a kind of with ginsenoside Rb
1With Rd be the notoginseng glycol-saponin composition of main component.
Another object of the present invention provides the preparation method of notoginseng glycol-saponin composition of the present invention.
Another purpose of the present invention provides the pharmaceutical applications of notoginseng glycol-saponin composition of the present invention.
A further object of the present invention provide notoginseng glycol-saponin composition of the present invention be used for the treatment of disease purposes.
For achieving the above object, a technical scheme of the present invention provides a kind of notoginseng glycol-saponin composition, and said composition is purified by Radix Notoginseng and obtained, and it is basically by ginsenoside Rb
1Form with Rd; Ginsenoside Rb wherein
1Content be 30～70wt%, be preferably 40～65wt%, most preferably be 50～65wt%; Ginsenoside Rd's content is 4～18wt%, is preferably 6～15wt%, most preferably is 10～13wt%; And ginsenoside Rb
1Be up to 80wt% with the content sum of Rd.
The molecular formula of the key component of notoginseng glycol-saponin composition provided by the invention and structural formula are as shown in following table 1:
Table 1.
The ginsenoside Rb that also can contain trace at notoginseng glycol-saponin composition described in the technique scheme of the present invention
2, Rb
3And/or Rc.
Notoginseng glycol-saponin composition provided by the invention not only has obvious anti-inflammatory and analgesic effect, and toxic and side effects is lower, has the characteristics of NSAID (non-steroidal anti-inflammatory drug), and is especially more remarkable to the anti-inflammatory analgesic action of edema impatient property inflammation and the chronic disease of granuloma.
Another technical scheme of the present invention provides the preparation method of notoginseng glycol-saponin composition of the present invention, and this method may further comprise the steps:
(1) with concentration be 50～90wt%, preferred 55～70wt%, most preferably from about the soak with ethanol of 60wt% is extracted Radix Notoginseng, used amount of alcohol is at least 3 times of used three seven weight, collects ethanol extract;
(2) make described ethanol extract by the styrene type macroporous resin post, preferably use the styrene type macroporous resin of nonpolar or low pole, these resins include but not limited to D101, D140, Dj-1 or D201;
(3) with concentration be 30～50wt%, preferred 35～45wt%, most preferably from about the ethanol of 40wt% carries out eluting to described styrene type macroporous resin post, preferably before carrying out eluting with described ethanol, water carries out eluting to the styrene type macroporous resin post, to remove water-solubility impurity; With
(4) with concentration be 50～70wt%, preferred 55～65wt%, most preferably from about the ethanol of 60wt% carries out eluting once more to the resin column through ethanol elution in the described step (3), collects eluent.
In step described in the technique scheme of the present invention (1) and step (4), use the about 60wt% of concentration of ethanol to be meant that its concentration in the acceptable error scope, is generally 60 ± 3wt%.Use the about 40wt% of concentration of ethanol to be meant that its concentration in the acceptable error scope, is generally 40 ± 2wt% in the described step (3).
In above-mentioned steps (1), step (3) and step (4), to the not too many restriction of the amount of alcohol of using.But for step (1), general used amount of alcohol is 3～15 times of used three seven weight.If used amount of alcohol is very little, then the immersion extraction is insufficient, if but the amount of alcohol of usefulness is too many, and will cause alcoholic acid waste and the energy cost of follow-up ethanol recycling step is increased.For step (3) and step (4), general used amount of alcohol is 1～15 times of used Radix Notoginseng amount equally.If used amount of alcohol is very little, then eluting is insufficient, if but the amount of alcohol of usefulness is too many, and will cause alcoholic acid waste and the energy cost of follow-up ethanol recycling step is increased.
In order to improve the efficient of extraction, before step described in the preparation method of notoginseng glycol-saponin composition of the present invention (1) is soaked extraction with ethanol to Radix Notoginseng, consider from the efficient that helps subsequent step, Radix Notoginseng need be pulverized.Preferably Radix Notoginseng powder is broken into particle size range " between the coarse powder and coarse powder of (Chemical Industry Press, publish in January, 2000) regulation of Chinese pharmacopoeia version in 2000, for the mode of pulverizing without any restriction.
Therefore, step described in the preparation method of notoginseng glycol-saponin composition of the present invention (1) preferred implementation is as follows:
(a) Radix Notoginseng is pulverized, get Radix Notoginseng powder;
(b) adopt that concentration is 50～90wt%, preferred 55～70wt%, most preferably from about the ethanol of 60wt% is to described step
(a) Radix Notoginseng powder of gained soaks, and used amount of alcohol is at least 2 times of used Radix Notoginseng powder weight; With
(c) adopt that concentration is 50～90wt%, preferred 55～70wt%, most preferably from about the ethanol of 60wt% is to described step
(b) Radix Notoginseng powder after the immersion of gained carries out percolation, and used amount of alcohol is at least 1 times of used Radix Notoginseng powder weight, collects percolate.
In step described in the technique scheme of the present invention (b) and step (c), use the about 60wt% of concentration of ethanol to be meant that its concentration in the acceptable error scope, is generally 60 ± 3wt%.
In above-mentioned steps (b), soak the middle used amount of alcohol of percolation of used amount of alcohol of Radix Notoginseng powder and step (c) and all do not have too many restriction.But the zone of reasonableness that soaks the used amount of alcohol of Radix Notoginseng powder is generally 2～4 times of used Radix Notoginseng powder weight, and the zone of reasonableness of the used amount of alcohol of percolation is generally 1～15 times of used Radix Notoginseng powder weight.If soak the used amount of alcohol of Radix Notoginseng powder and the lower limit that the used amount of alcohol of percolation is lower than above-mentioned scope, then can not soak the active ingredient that extracts in the Radix Notoginseng fully effectively, if but used amount of alcohol surpasses the upper limit of above-mentioned scope, extraction efficiency is not had raising again yet, but also can cause alcoholic acid waste and the energy cost of follow-up ethanol recycling step is increased.
If desired, also can adopt silicagel column that the eluent that above-mentioned steps (4) makes is further purified, collect eluent again.Available silicagel column includes but not limited to chromatographic silica gel SG11, SG20 series, and used eluant is the mixed solvent of ethyl acetate, second alcohol and water, and volume ratio is 7: 4: 1 between them.Preferably, before last silicagel column, earlier the eluent that step (4) is made is evaporated to respect to 1.1 times of the density of water, admix in the equal-volume silica gel, behind low temperature (50 ± 5 ℃) vacuum drying with the silica gel that contains medicine of gained, add on the silicagel column that has prepared, carry out silica gel column chromatography refinement again.Collection contains ginsenoside Rb
1Eluent with Rd.
If desired, the eluent that step (4) can be collected or again eluent concentrate, panasadiol saponio alcohol extractum, and above-mentioned panasadiol saponio alcohol extractum carried out drying.Described concentration step can adopt the method for any routine, but preferably adopts the method for concentrating under reduced pressure.Described drying steps can adopt various means, as spray drying, drying under reduced pressure, vacuum drying etc.
In order to reduce cost, in the preparation method of notoginseng glycol-saponin composition of the present invention, the ethanol in the percolate of collecting in ethanol extract of collecting in the also recyclable described step (1) or the step (c) preferably adopts the reclaim under reduced pressure mode.
The preparation method of notoginseng glycol-saponin composition provided by the invention can effectively be separated the notoginseng diol saponins effective ingredient in the Radix Notoginseng total arasaponins; And used solvent safety, cheap and easy to get, the noresidue of this preparation method, and the also recyclable utilization of solvent, greatly reduce preparation cost.
Another technical scheme of the present invention provides notoginseng glycol-saponin composition of the present invention to be used to prepare the application of the medicine for the treatment of rheumatic, rheumatoid arthritis.
Notoginseng glycol-saponin composition provided by the invention can be made into various dosage forms, for example, and dosage forms such as granule, mixture, tablet, powder, honeyed pill, capsule, injection, drop, patch.The method and the used auxiliary agent that prepare these dosage forms are known to those skilled in the art, for example, can be referring to " pharmacy of Chinese materia medica " (Shanghai science tech publishing house, in November, 1986 publication), " pharmaceutic adjuvant complete works " (Sichuan science tech publishing house, publication in January nineteen ninety-five), " Chinese pharmacopoeia version in 2000 one (Chemical Industry Press, publish in January, 2000) etc.
Content for the contained notoginseng glycol-saponin composition of the present invention of medicine list of the present invention agent does not have concrete restriction, for example, and can be 50～500 milligrams/agent.Route of administration for pharmaceutical preparation of the present invention does not have too much restriction yet, for example can be by modes such as oral, filling stomach, intramuscular injection, intravascular injection, transdermal, duodenal administration, intranasal administrations.
Above-mentioned preparation of the present invention can be used for dissipating blood stasis, and subduing swelling and relieving pain is used for swelling and ache and the rheumatic arthritis of Western medicine diagnose, the treatment of swelling and ache of rheumatoid arthritis of wind, cold, each syndrome of arthralgia chiefly caused by damp pathogen.
The present invention also provides a kind of method for the treatment of rheumatic, rheumatoid arthritis, it is characterized in that, uses the notoginseng glycol-saponin composition of the present invention of effective dose for the patient who needs treatment.Described patient comprises the people, also comprises animals such as cat, Canis familiaris L., orangutan, monkey.Described effective dose can change to some extent with factors such as the disease of patient order of severity, body weight, body constitution, age, ill history.But doctor or pharmacists have the ability to determine suitable dose for different patients.For example, can be by 1～6mg/kg body weight/day, preferably take the effective ingredient of medicine of the present invention, notoginseng glycol-saponin composition promptly of the present invention to the patient by 3～4mg/kg body weight/day.
The specific embodiment
Embodiment 1
Use Universalpulverizer (available from sky, Shanghai and pharmaceutical machine factory, model GF-300) pulverizes the notoginseng drying rhizome 150kg (place of production: Yunnan Province Wenshan Prefecture), to particle size range 10 orders～24 purpose Radix Notoginseng coarse powder, with the concentration of 2 times of medical material weight is to insert the percolation bucket behind the above-mentioned Radix Notoginseng coarse powder of 60wt% soak with ethanol, concentration with 10 times of medical material weight is that 60wt% ethanol carries out percolation to wet feed, collect percolate, get Radix Notoginseng total arasaponins alcohol extractum behind the ethanol in the reclaim under reduced pressure percolate.Above-mentioned Radix Notoginseng total arasaponins alcohol extractum is mixed with the aqueous solution of 10 times of medical material weight with pure water, with sample on the obtained aqueous solution to styrene type macroporous resin D140 (available from Chengdu Zhonglan Chenguang Chemical Inst) post, first purified water eluting with 9 times of medical material weight, be the 40wt% ethanol elution to the resin column of purified water elution with the concentration of 9 times of medical material weight again, flow velocity be 0.2 times of column volume/hour, at last to carrying out eluting once more with the 60wt% ethanol of 9 times of medical material weight amounts through the resin column of ethanol elution, flow velocity be 0.2 times of column volume/hour, collect the eluent of 60wt% ethanol elution.This eluent is evaporated to respect to 1.1 times of the density of water, above-mentioned concentrated solution is admixed among the equal-volume chromatographic silica gel SG11 low temperature (50 ± 5 ℃) vacuum drying.With the above-mentioned silica gel volume of admixing concentrated solution is benchmark, and the chromatographic silica gel SG11 dress post with 23 times of volumes adds to the silica gel that contains medicine behind the vacuum drying on the silicagel column that has prepared again, carries out silica gel column chromatography refinement.With the ethyl acetate of 4 times of column volumes, the mixed solvent of second alcohol and water (volume ratio is 7: 4: 1) is that eluant carries out eluting to silicagel column, collects to contain ginsenoside Rb
1Stream part with Rd.Collected stream part is carried out concentrating under reduced pressure gets pure extractum, and pure extractum vacuum drying system is got dry extract, and pulverize the pulverous notoginseng glycol-saponin composition of 5kg.For simplicity's sake, hereinafter abbreviate notoginseng glycol-saponin composition as PDS sometimes.
By high performance liquid chromatography, the employing octadecylsilane chemically bonded silica is a filler, is that mobile phase is measured Rb with acetonitrile-water (volume ratio is 32: 68)
1Content, be the content that mobile phase is measured Rd with acetonitrile-water (volume ratio is 35: 65), the detection wavelength is 210nm, measures Rb among the PDS that embodiment 1 makes respectively
1Be respectively 59.31wt% and 15.1wt% with the content of Rd.
Embodiment 2～5
According to embodiment 1 described identical method and step, the ethanol that adopts variable concentrations, Different Weight to the Radix Notoginseng coarse powder soak, percolation and eluting, obtained following compositions of the present invention, the result is as shown in table 2 below:
Table 2.
| The embodiment numbering | Used pseudo-ginseng weight | Immersion, percolation concentration of ethanol and consumption | Adopt resin, twice eluting resin concentration of ethanol and consumption | The weight of PDS and the content of key component |
| Embodiment 2 | 3kg | Soaking with concentration of alcohol is 60wt%; Consumption is that 2 times of medicinal material weight diacolation concentration of alcohol are 60wt%, and consumption is 9 times of medicinal material weight | D101 (available from Tianjin insecticide factory) the wash-out first time is 40wt% with the concentration of ethanol; Consumption be 9 times of medicinal material weight for the second time wash-outs be 60wt% with the concentration of ethanol, consumption is 9 times of medicinal material weight | The weight of PDS: 0.0945kg Rb 1：59.86wt％ Rd：14.90wt％ |
| Embodiment 3 | 3kg | Soaking with concentration of alcohol is 60wt%; Consumption is that 2 times of medicinal material weight diacolation concentration of alcohol are 60wt%, and consumption is 9 times of medicinal material weight | D101 (available from Tianjin insecticide factory) the wash-out first time is 40wt% with the concentration of ethanol; Consumption be 9 times of medicinal material weight for the second time wash-outs be 60wt% with the concentration of ethanol, consumption is 8 times of medicinal material weight | The weight of PDS: 0.0885kg Rb 1：60.18wt％ Rd：13.49wt％ |
| Embodiment 4 | 0.1kg | Soaking with concentration of alcohol is 60wt%; Consumption is that 2 times of medicinal material weight diacolation concentration of alcohol are 60wt%, and consumption is 9 times of medicinal material weight | D101 (available from Tianjin insecticide factory) the wash-out first time is 40wt% with the concentration of ethanol; Consumption be 9 times of medicinal material weight for the second time wash-outs be 70wt% with the concentration of ethanol, consumption is 7 times of medicinal material weight | The weight of PDS: 0.0039kg Rb 1：51.78wt％ Rd：12.15wt％ |
| Embodiment 5 | 0.1kg | Soaking with concentration of alcohol is 60wt%; Consumption is that 2 times of medicinal material weight diacolation concentration of alcohol are 60wt%, and consumption is 9 times of medicinal material weight | D101 (available from Tianjin insecticide factory) the wash-out first time is 40wt% with the concentration of ethanol; Consumption be 9 times of medicinal material weight for the second time wash-outs be 60wt% with the concentration of ethanol, consumption is 9 times of medicinal material weight | The weight of PDS: 0.004kg Rb 1：51.70wt％ Rd：13.05wt％％ |
Embodiment 6
Get the dried cream 100g of exsiccant PDS that embodiment 1 makes, pulverized 100 mesh sieves, add starch 97.5g and microcrystalline Cellulose 2.5g, mixing is dissolved in the ethanol that concentration is 50wt%, and drying under reduced pressure is pulverized, and loads and makes 1000 of capsules or 2000.
Test example 1 analgesia drug effect
PDS is to the analgesic activity test of mice whipping reaction
Use 60 mices, be divided into 2 matched groups and 4 experimental grouies at random, 10 every group.With normal saline the PDS powder that embodiment 1 makes is made into dense suspension, the dosage of 4 experimental grouies is respectively 400mg/kg, 200mg/kg, 100mg/kg, 50mg/kg, negative control group gives the normal saline with capacity such as maximal dose experimental grouies, and positive controls gives positive control medicine indometacin 5mg/kg.Each group according to predetermined close gastric infusion every day once, successive administration 4 days, after administration in the 4th day 30,90 and 120 minutes, in 50 ± 0.5 ℃ of water-baths, measure the incubation period of mice whipping reaction respectively, as logical threshold index, carry out the analysis of t inspection statistics, the result is as shown in table 3 below:
Table 3.
| Group | Dosage mg/kg | Different time TFL after the administration (x ± SD.) (second) | ||
| 30 fens kinds after the administration | 90 fens kinds after the administration | 120 fens kinds after the administration | ||
| Negative control group | 0 | 1.299±0.454 | 1.322±0.354 | 1.490±0.3480 |
| Positive controls (indometacin) | 5 | 2.202±0.434** | 2.244±0.495** | 2.1140.374** |
| PDS | 400 | 1.816±0.524* | 1.989±0.517** | 2.073±0.376** |
| PDS | 200 | 1.772±0.340* | 1.918±0.404** | 1.852±0.358* |
| PDS | 100 | 1.305±0.399 | 1.961±0.291** | 1.730±0.305 |
| PDS | 50 | 1.514±0.426 | 1.652±0.297 | 1.584±0.291 |
*P＜0.05 **P＜0.01 ***P＜0.001
PDS is to the analgesic activity test of rat whipping reaction
Use 60 rats, be divided into 2 matched groups and 4 experimental grouies at random, 10 every group.With normal saline the PDS powder that embodiment 1 makes is made into dense suspension, the dosage of 4 experimental grouies is respectively 400mg/kg, 200mg/kg, 100mg/kg, 50mg/kg, negative control group gives the normal saline with capacity such as maximal dose experimental grouies, and positive controls gives positive control medicine indometacin 5mg/kg.Each group according to predetermined close gastric infusion every day once, successive administration 3 days, after administration in the 3rd day 30,90 and 120 minutes, in 50 ± 0.5 ℃ of water-baths, measure the incubation period of rat whipping reaction respectively, as logical threshold index, carry out the analysis of t inspection statistics, the result is as shown in table 4 below:
Table 4.
| Group | Dosage mg/kg | Different time TFL after the administration (x ± SD.) (second) | ||
| 30 fens kinds after the administration | 90 fens kinds after the administration | 120 fens kinds after the administration | ||
| Negative control group | 0 | 3.600±0.840 | 4.101±0.956 | 3.849±0.993 |
| Positive controls (indometacin) | 5 | 3.976±0.937 | 5.689±1.436* | 4.764±0.835* |
| PDS | 400 | 4.450±0.830* | 5.440±1.303* | 5.326±1.726* |
| PDS | 200 | 4.695±1.133* | 5.629±1.149* | 3.864±0.739 |
| PDS | 100 | 4.783±1.558 | 5.422±1.290* | 4.434±0.869 |
| PDS | 50 | 3.345±1.164 | 4.523±1.403 | 3.669±1.295 |
*P＜0.05 **P＜0.01 ***P＜0.001
This result of the test proves: the PDS gastric infusion 400mg/kg that embodiment 1 makes, each dosage group of 200mg/kg, 100mg/kg are to the anti-inflammatory and analgesic effects of rat, two kinds of animals of mice highly significant.
Test example 2 antiinflammatory drug effects---rat assist agent arthritis is tested
Use 50 rats, be divided into 2 matched groups and 3 experimental grouies at random, 10 every group.With normal saline the PDS powder that embodiment 1 makes is made into dense suspension, the dosage of 3 experimental grouies is respectively 200mg/kg, 100mg/kg, 50mg/kg, negative control group gives the normal saline with capacity such as maximal dose experimental grouies, and positive controls gives positive control medicine indometacin 2.5mg/kg.What cause that scorching model system will prepare in advance causes scorching adjuvant 0.1ml intradermal injection to the right back sufficient pad of every rat portion.Each is organized in causing scorching preceding 4 days and begins to give respectively normal saline, PDS suspension of the present invention or indometacin, organizes predetermined close gastric infusion every day 1 time according to each.After the last administration, caused inflammation in 30 minutes, observe causing scorching back 18 hours and the 8th day swollen degree of adjuvant injection parapodum, and carry out the analysis of t inspection statistics.The result shows: each dosage group of PDS 200mg/kg, the 100mg/kg that embodiment 1 makes, 50mg/kg all can alleviate the swollen degree of foot, and tangible antiinflammation is arranged, and can prevent and treat the generation of adjuvant-induced arthritis.
As everyone knows, rat assist agent arthritis is an immune inflammation model, and its pathogeny is similar to people's rheumatoid arthritis with pathological change.In the different onset stage of this model, the antiinflammatory action of highly significant all can appear in the PDS that embodiment 1 makes, and its action intensity also is not less than indometacin.Though the pathogeny of rheumatic arthritis and rheumatoid arthritis is still not fully aware of,, result of the test shows: the PDS that embodiment 1 makes can treat rheumatisms such as rheumatoid arthritis.
3 acute toxicity tests of test example
The acute toxicity test of mouse stomach administration
Use 80 mices, be divided into 4 groups at random, 20 every group.Each is organized dosage and is respectively 1000mg/kg, 1600mg/kg, 2000mg/kg, 5000mg/kg.With normal saline the PDS powder that embodiment 1 makes is made into dense suspension, fasting is 4 hours before the mice administration, observes 7 days according to behind each group predetermined close gastric infusion 1 time, the no significant discomfort of each group, growth promoter is normal, and experiment is carried out pathologic finding, no abnormality seen after finishing.The result shows: the PDS oral administration that embodiment 1 makes is 5000mg/kg to the maximum tolerated dose of mice, and this medicine is less to the acute toxicity of mice, and the inhibitory action that occurs after the administration begins after about 2 hours to recover.
The acute toxicity test of mouse vein administration
Use 40 mices, be divided into 4 groups at random, 10 every group.Each is organized dosage and is respectively 400mg/kg, 360mg/kg, 320mg/kg, 288mg/kg, and agent is apart from than being 1: 0.9.With normal saline the PDS powder that embodiment 1 makes is made into PDS solution, organize predetermined close intravenous administration 1 time according to each, calculate LD50 (medicine median lethal dose(LD 50): the dosage that promptly causes the death of laboratory animal half) be 371.959 (352.847～392.107) mg/kg according to experimental result at the acute toxicity testing Chinese medicine, symptom such as motionless under inhibition, accelerated breathing and the volt appears before the death, and dead then.
Although describe the present invention in conjunction with the preferred embodiments, but the present invention is not limited to the foregoing description, should be appreciated that, under the guiding of the present invention's design, those skilled in the art can carry out various modifications and improvement, and claims have been summarized scope of the present invention.
Claims (16)
1. notoginseng glycol-saponin composition, said composition are purified by Radix Notoginseng and are obtained, and it is basically by ginsenoside Rb
1Form with Rd, wherein ginsenoside Rb
1Content be 30～70wt%, ginsenoside Rd's content is 4～18wt%, and ginsenoside Rb
1Be up to 80wt% with the content sum of Rd.
2. notoginseng glycol-saponin composition according to claim 1 is characterized in that, described ginsenoside Rb
1Content be 40～65wt%, described ginsenoside Rd's content is 6～15wt%.
3. notoginseng glycol-saponin composition according to claim 2 is characterized in that, described ginsenoside Rb
1Content be 50～65wt%, described ginsenoside Rd's content is 10～13wt%.
4. each described notoginseng glycol-saponin composition of claim 1-3, it is granule, mixture, tablet, powder, honeyed pill, capsule, injection, drop or patch.
5. the preparation method of a notoginseng glycol-saponin composition, this method may further comprise the steps:
(1) be the soak with ethanol extraction Radix Notoginseng of 50～90wt% with concentration, used amount of alcohol is at least 3 times of used three seven weight, collects ethanol extract;
(2) make described ethanol extract by the styrene type macroporous resin post;
(3) be that the ethanol of 30～50wt% carries out eluting to described styrene type macroporous resin post with concentration; With
(4) be that the ethanol of 50～70wt% carries out eluting once more to the resin column through ethanol elution in the described step (3) with concentration, collect eluent.
6. the preparation method of notoginseng glycol-saponin composition according to claim 5 is characterized in that, following the finishing of described step (1):
(a) Radix Notoginseng is pulverized, get Radix Notoginseng powder;
(b) adopting concentration is that the ethanol of 50～90wt% soaks the Radix Notoginseng powder of described step (a) gained, and used amount of alcohol is at least 2 times of used Radix Notoginseng powder weight; With
(c) adopting concentration is that the ethanol of the 50～90wt% Radix Notoginseng powder after to the immersion of described step (b) gained carries out percolation, and used amount of alcohol is at least 1 times of used Radix Notoginseng powder weight, collects percolate.
7. the preparation method of notoginseng glycol-saponin composition according to claim 6 is characterized in that, used concentration of ethanol is 55～70wt% in described step (b) and step (c).
8. the preparation method of notoginseng glycol-saponin composition according to claim 7 is characterized in that, used concentration of ethanol is about 60wt% in described step (b) and step (c).
9. the preparation method of notoginseng glycol-saponin composition according to claim 5 is characterized in that, is 35～45wt% in described step (3) eluting resin concentration of ethanol, and used amount of alcohol is at least 1 times of used Radix Notoginseng powder weight.
10. the preparation method of notoginseng glycol-saponin composition according to claim 9 is characterized in that, is about 40wt% in described step (3) eluting resin concentration of ethanol.
11. the preparation method of notoginseng glycol-saponin composition according to claim 5 is characterized in that, is 55～65wt% in described step (4) eluting resin concentration of ethanol, used amount of alcohol is at least 1 times of used Radix Notoginseng powder weight.
12. the preparation method of notoginseng glycol-saponin composition according to claim 11 is characterized in that, is about 60wt% in described step (4) eluting resin concentration of ethanol.
13. the preparation method of notoginseng glycol-saponin composition according to claim 5 is characterized in that, also comprises: the eluent that adopts silicagel column that above-mentioned steps (4) is made carries out purification and gets eluent again.
14. the preparation method according to each described notoginseng glycol-saponin composition of claim 5-13 is characterized in that, and is further comprising the steps of: with the eluent collected or again eluent concentrate panasadiol saponio alcohol extractum.
15. the preparation method of notoginseng glycol-saponin composition according to claim 14 is characterized in that, and is further comprising the steps of: described panasadiol saponio alcohol extractum is carried out drying.
16. each described notoginseng glycol-saponin composition of claim 1-3 is used to prepare the application of the medicine for the treatment of rheumatic, rheumatoid arthritis.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100906050A CN100502880C (en) | 2004-11-09 | 2004-11-09 | Notoginseng glycol-saponin composition and its preparation method and use |
| PCT/CN2004/001562 WO2006050642A1 (en) | 2004-11-09 | 2004-12-29 | A composition containing panaxadial saponins and its preparation and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100906050A CN100502880C (en) | 2004-11-09 | 2004-11-09 | Notoginseng glycol-saponin composition and its preparation method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1771977A true CN1771977A (en) | 2006-05-17 |
| CN100502880C CN100502880C (en) | 2009-06-24 |
Family
ID=36336196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100906050A Active CN100502880C (en) | 2004-11-09 | 2004-11-09 | Notoginseng glycol-saponin composition and its preparation method and use |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN100502880C (en) |
| WO (1) | WO2006050642A1 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010078730A1 (en) * | 2008-12-29 | 2010-07-15 | 广东泰禾医药科技有限公司 | Preparation of ginsenoside-rd propylene glycol aqueous solution and new use thereof in anti-inflammation, immunosuppression and anti organ-graft rejection |
| CN101007035B (en) * | 2007-01-25 | 2010-12-01 | 上海中药创新研究中心 | Application of notoginseng glycol saponins for treating memory deterioration |
| CN1869058B (en) * | 2006-06-21 | 2012-01-11 | 海南亚洲制药有限公司 | Method of preparing trialcohol group ginseng saponine and bialcohol group ginseng saponine from notoginseng |
| CN101390871B (en) * | 2007-09-18 | 2012-01-18 | 北京本草天源药物研究院 | Ginsenoside Rb1 containing impurity ginsenoside Rd |
| CN1869057B (en) * | 2006-06-21 | 2012-03-07 | 海南亚洲制药有限公司 | Preparation method of trialcohol group ginseng saponine and bialcohol group ginseng saponine |
| CN1869059B (en) * | 2006-06-21 | 2012-04-18 | 海南亚洲制药有限公司 | Method of preparing ginseng saponine monomer from ginseng leaf |
| CN104173358A (en) * | 2014-08-27 | 2014-12-03 | 哈尔滨珍宝制药有限公司 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
| CN105998042A (en) * | 2016-06-02 | 2016-10-12 | 上海中医药大学附属龙华医院 | Use of panax notoginseng total saponin extract in promoting lymphangion genesis |
| CN116036105A (en) * | 2021-10-28 | 2023-05-02 | 上海中医药大学附属龙华医院 | Application of medicine for treating lymphedema |
| CN116492355A (en) * | 2023-06-26 | 2023-07-28 | 云南与诺生物工程有限责任公司 | Use of a composition for the preparation of a medicament for alleviating pain |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010155787A (en) * | 2008-12-26 | 2010-07-15 | Maruzen Pharmaceut Co Ltd | Anti-inflammatory, anti-aging agent, antiobestic agent, hair restorer, cosmetic and food and drink for beautification |
-
2004
- 2004-11-09 CN CNB2004100906050A patent/CN100502880C/en active Active
- 2004-12-29 WO PCT/CN2004/001562 patent/WO2006050642A1/en active Application Filing
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1869058B (en) * | 2006-06-21 | 2012-01-11 | 海南亚洲制药有限公司 | Method of preparing trialcohol group ginseng saponine and bialcohol group ginseng saponine from notoginseng |
| CN1869057B (en) * | 2006-06-21 | 2012-03-07 | 海南亚洲制药有限公司 | Preparation method of trialcohol group ginseng saponine and bialcohol group ginseng saponine |
| CN1869059B (en) * | 2006-06-21 | 2012-04-18 | 海南亚洲制药有限公司 | Method of preparing ginseng saponine monomer from ginseng leaf |
| CN101007035B (en) * | 2007-01-25 | 2010-12-01 | 上海中药创新研究中心 | Application of notoginseng glycol saponins for treating memory deterioration |
| CN101390871B (en) * | 2007-09-18 | 2012-01-18 | 北京本草天源药物研究院 | Ginsenoside Rb1 containing impurity ginsenoside Rd |
| WO2010078730A1 (en) * | 2008-12-29 | 2010-07-15 | 广东泰禾医药科技有限公司 | Preparation of ginsenoside-rd propylene glycol aqueous solution and new use thereof in anti-inflammation, immunosuppression and anti organ-graft rejection |
| CN104173358A (en) * | 2014-08-27 | 2014-12-03 | 哈尔滨珍宝制药有限公司 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
| CN105998042A (en) * | 2016-06-02 | 2016-10-12 | 上海中医药大学附属龙华医院 | Use of panax notoginseng total saponin extract in promoting lymphangion genesis |
| CN116036105A (en) * | 2021-10-28 | 2023-05-02 | 上海中医药大学附属龙华医院 | Application of medicine for treating lymphedema |
| CN116492355A (en) * | 2023-06-26 | 2023-07-28 | 云南与诺生物工程有限责任公司 | Use of a composition for the preparation of a medicament for alleviating pain |
| CN116492355B (en) * | 2023-06-26 | 2023-09-29 | 云南与诺生物工程有限责任公司 | Use of a composition for the preparation of a medicament for alleviating pain |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006050642A1 (en) | 2006-05-18 |
| CN100502880C (en) | 2009-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1108807C (en) | Chinese herbs extract | |
| CN101214270B (en) | Acanthopanax senticosus effective fraction extract, preparation and application thereof | |
| CN101711805A (en) | Medicine composition for treating rheumatoid arthritis and preparation thereof | |
| CN100502880C (en) | Notoginseng glycol-saponin composition and its preparation method and use | |
| CN1785284A (en) | Medicinal composition containing flowery knotwood root | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| CN102119964A (en) | Extract of preventing and treating coronary heart disease and stenocardia and preparation method and application thereof | |
| CN103386022A (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN1709417A (en) | Ainsliaea fragrans champ extract and its preparing method | |
| CN1422622A (en) | Herba-Epimedii extract for treating prostatic hyerplasia and use in preparing medicine | |
| CN1857472A (en) | Ginsenoside composition preparation and its preparing process | |
| CN1771978A (en) | Notoginseng triol-saponin composition and its prepn and use | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN101040891A (en) | Preparation method and application of tripterygium hypoglaucum alkaloids | |
| CN1686200A (en) | Tulip poplar extract, refined extract and its application in medicine preparation | |
| CN1068782C (en) | Anti-cancer medicine with extracts from goldenrain and the preparation thereof | |
| CN1319578C (en) | Prescription of Chinese medicine compound preparation, its preparation method and use | |
| CN101077364A (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
| CN1887316A (en) | Chinese medicine composition and its prepn process and application | |
| CN1299720C (en) | Medicine composition for curing cold | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN101461842B (en) | Method for extracting anti-tumor effective component of Prunella vulgaris and application of extract thereof in preparing anti-tumor medicament | |
| CN1254260C (en) | Medicine composition containing epimedium extract | |
| CN100588411C (en) | Medicine composition containing franchet groundcherry steride | |
| CN1843407A (en) | Compound drop pills with Chinese medicinal effective part and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Chengdu Chinese Medicine University Huasun Pharmaceutical Co., Ltd. Assignor: Pharmaceutical Factory, Chengdu Huashen Group Corp., Ltd. Contract record no.: 2011510000214 Denomination of invention: Notoginseng glycol-saponin composition and its prepn and use Granted publication date: 20090624 License type: Exclusive License Open date: 20060517 Record date: 20110826 |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 610000 Sichuan city of Chengdu Province Southwest Economic Development Zone Jinhua Road two No. 3 Patentee after: Chengdu Taihe health technology group Limited by Share Ltd Huashen pharmaceutical factory Address before: 610000 Sichuan city of Chengdu Province Southwest Economic Development Zone Jinhua Road two No. 3 Patentee before: Pharmaceutical Factory, Chengdu Huashen Group Corp., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180508 Address after: 611731 B301-B310 room 3, 1168 Shu Xin Road, Chengdu high tech Zone, Sichuan. Patentee after: Chengdu Chinese Medicine University Huasun Pharmaceutical Co., Ltd. Address before: 610000 No. 3, two Jinhua Road, southwest aviation Economic Development Zone, Chengdu, Sichuan Patentee before: Chengdu Taihe health technology group Limited by Share Ltd Huashen pharmaceutical factory |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 610000 room b301-b311, 3rd floor, No. 1168 Shuxin Avenue, hi tech Zone, Chengdu, Sichuan Patentee after: Chengdu dahuashen Pharmaceutical Co.,Ltd. Address before: 611731 B301-B310 room 3, 1168 Shu Xin Road, Chengdu high tech Zone, Sichuan. Patentee before: CHENGDU UNIVERSITY OF TCM HUASUN PHARMACEUTICAL Co.,Ltd. |